Associated Papers
Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance.
Raaijmakers MI et al.
Oncotarget, 2016
27791198 (PubMed )
Supplement: oncotarget-07-77163-s002.xlsx › Patient_1_early_met_1
Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes.
Graubert TA et al.
Nature Genetics, 2011
22158538 (PubMed )
Supplement: NIHMS337712-supplement-1.pdf
Select a paper to view details